Bechtel Medical said on November 10 that FDA cleared Wound VOX, which it describes as the first 510(k) cleared system to combine negative pressure wound therapy with topical oxygen in one unit. The device runs three modes: continuous negative pressure, intermittent negative pressure, and intermittent negative pressure with adjunctive topical oxygen therapy.
The Phoenixville, Pennsylvania company plans a limited commercial release in December 2026 and is recruiting durable medical equipment distribution partners. Founder and chief executive John Gvodas runs the company with co-founder Christina Gvodas.
Bechtel cites a 2025 meta-analysis of 11 randomized trials on combined negative pressure and topical oxygen, and states plainly that those results did not come from studies of Wound VOX. Keeping that line clean is the harder part of the launch, once the marketing copy starts quoting healing rates.